EUCTR2004-001093-11-IT进行中（未招募）不适用
A Treatment Protocol for Patients Continuing from a Prior SU011248 protocol
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- PFIZER
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Treatment Protocol for Patients Continuing from a Prior SU011248 ProtocolThis is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248 treatment. Included in this protocol will be patients assigned to placebo in a previous study who did not qualify for crossover within the original protocol due to declining health status (eg, performance status lower than crossover eligibility criterionMedDRA version: 7.1Level: LLYClassification code 10062427EUCTR2004-001093-11-SEPfizer Ltd
进行中（未招募）
不适用
A Treatment Protocol for Patients Continuing from Prior SU0011248 ProtocolGastrointestinal stromal tumorEUCTR2004-001093-11-ESPfizer SA
进行中（未招募）
1 期
A Treatment Protocol for Patients Continuing from a Prior SU011248 ProtocolThis is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248 treatment. Included in this protocol will be patients assigned to placebo in a previous study who did not qualify for crossover within the original protocol due to declining health status (eg, performance status lower than crossover eligibility criterionMedDRA version: 7.1 Level: LLY Classification code 10062427EUCTR2004-001093-11-GBPfizer Global Research and Development
进行中（未招募）
1 期
A Treatment Protocol for Patients Continuing from a Prior SU011248 ProtocolThis is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248 treatment. Included in this protocol will be patients assigned to placebo in a previous study who did not qualify for crossover within the original protocol due to declining health status (eg, performance status lower than crossover eligibility criterionMedDRA version: 7.1Level: LLYClassification code 10062427EUCTR2004-001093-11-NLPfizer
进行中（未招募）
不适用
A Treatment Protocol for Patients Continuing from a Prior SU011248 ProtocolThis is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248 treatment. Included in this protocol will be patients assigned to placebo in a previous study who did not qualify for crossover within the original protocol due to declining health status (eg, performance status lower than crossover eligibility criterionMedDRA version: 7.1Level: LLYClassification code 10062427EUCTR2004-001093-11-GRPfizer Hellas A.E.